North America Anti-Inflammatory Drugs Size, Scope and Forecast | Use Key Players

 The global anti-inflammatory drugs market size stood at USD 93.88 billion in 2019 and is projected to reach USD 191.42 billion by 2027, exhibiting a CAGR of 9.3% during the forecast period

According to a new study from UTHealth Houston and other institutions, an anti-inflammatory drug may have the ability to treat systemic inflammation and brain damage in patients with severe COVID-19 and greatly lower their risk of dying.

A group of researchers led by Louise D. McCullough, MD, PhD, professor and Roy M. and Phyllis Gough Huffington Distinguished Chair in the Department of Neurology at UTHealth Houston, conducted a multi-site, randomised, controlled trial. Aaron M. Gusdon, MD, assistant professor in the Vivian L. Smith Department of Neurosurgery with McGovern Medical School at UTHealth Houston; H. Alex Choi, MD, associate professor in the department as well.

The trial’s findings were released in Science Translational Medicine today. 24 individuals with severe COVID-19 were included in the study and randomly assigned to receive either a single intravenous dosage of placebo or OP-101 at 2, 4, or 8 mg/kg. The standard of therapy, which included corticosteroids, was given to all patients.

Get a Sample Copy of the Report at – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102825

According to Gusdon, the study’s first author, “OP-101 is a novel nanotherapeutic drug that selectively targets active macrophages and microglia, the key immune cells in the brain. We were thrilled to provide this medication to these critically ill patients at Memorial Hermann Hospital because of its exceptional safety profile.

“It is incredibly intriguing to consider the idea that this therapy may also help patients with other conditions that trigger systemic inflammatory responses, including different types of brain injury." A nanotherapeutic substance called OP-101 has been tested in a number of animal models of inflammatory disease and has demonstrated superior anti-inflammatory and anti-oxidant effects. More than 300 million individuals have been infected by the COVID-19 pandemic, and more than 5 million have died as a result.

The study’s senior author is Sujatha Kannan, MD, professor in the Department of Anesthesiology and Critical Care Medicine at Baltimore, Maryland’s Johns Hopkins University School of Medicine. The medical school’s Nauder Faraday, MD, and Rangaramanujam M. Kannan, PhD, as well as the Bloomberg School of Public Health’s Derek K. Ng, PhD, were the other Johns Hopkins University co-authors.

Key players covered in the global Anti-Inflammatory Drugs Market research report:

  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Eli Lilly and Company
  • Amgen Inc.
  • Biogen

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Comments

Post a Comment

Popular posts from this blog

US Market Trends For Computer-Assisted & Robotics-Assisted Surgery

  In the medical industry, adoption of new cutting-edge technology is slow compared to other industries, such as the automotive industry. 1  Computer-assisted and robotic-assisted surgery (CAS and RAS, respectively) have been around for decades, yet a small percentage of procedures performed take advantage of the innovative solutions available on the market today. In coming years, the number of procedures using robotics and surgical navigation is predicted to increase at a double-digit rate year over year to reach over 6 million procedures by 2028. 2  This rise in CAS and RAS can be attributed to the predicted increase in the utilization of navigation systems and robotic devices as more companies launch new or next-generation systems for assisted surgery. Reasons For Slow CAS And RAS Adoption Some argue that using CAS and RAS is not worth the time and monetary investment, as using this technology often increases procedure planning time and reduces the number of procedures...
Read more

Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer

  Neoadjuvant Nivolumab Plus Chemo Approved in Canada for Treatment of Resectable Non-Small Cell Lung Cancer   Health Canada approved nivolumab in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer prior to surgery. Nivolumab (Opdivo) plus platinum-doublet chemotherapy has been approved by Health Canada for the treatment of certain patients with resectable non–small cell lung cancer, according to Bristol Meyers Squibb. The approval was based on results from the phase 3 CheckMate 816 trial (NCT02998528), in which neoadjuvant nivolumab plus chemotherapy resulted in a 37% reduction in risk of disease progression, recurrence, or death vs chemotherapy alone among patients with resectable NSCLC (HR, 0.63; 97.38%, 0.43-0.91;  P  = .005). The median event-free survival (EFS) with nivolumab/chemotherapy was 31.6 months vs 20.8 months with chemotherapy alone. Improvement in the rate of pathologica...
Read more

USA – Overview of Prothrombin Complex Concentrate Industry and Healthcare Statistics in 2022

Image
The global   Prothrombin Complex Concentrate (PCC) market size  was valued at USD 695.3 million in 2019 and is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6 % during the forecast period Abstract Left ventricular assist devices (LVADs) require careful therapeutic anticoagulation with warfarin to prevent pump thrombosis. However, the best method to reverse warfarin for elective LVAD conversion surgery with massive bleeding remains unclear. We report the case of a 39-year-old Japanese man who was administered a four-factor prothrombin complex concentrate (4F-PCC) as warfarin reversal when he underwent conversion surgery from paracorporeal LVAD to implantable LVAD. 4F-PCC with co-administration of vitamin K reduced the international normalized ratio and R time in TEG6s (Haemonetics Corporation, USA) immediately. The effect was prolonged, and good hemostasis was achieved. 4F-PCC with vitamin K provided good hemostasis in our patient; therefore, 4F-PCC co...
Read more